Intestinal efflux transporters and drug absorption.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425255.4.7.923 PMID 18624680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

  2008cited by this paper
• Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats.

  2008cited by this paper
• Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates.

  2008cited by this paper
• Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1)

  2007cited by this paper
• Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines

  2007cited by this paper
• Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport

  2007cited by this paper
• Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

  2007cited by this paper
• Site‐specific bidirectional efflux of 2,4‐dinitrophenyl‐S‐glutathione, a substrate of multidrug resistance‐associated proteins, in rat intestine and Caco‐2 cells

  2007cited by this paper
• Induction of Intestinal P‐glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol

  2007cited by this paper
• The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

  2007cited by this paper
• The apical conjugate efflux pump ABCC2 (MRP2)

  2007cited by this paper
• Regional Expression and Activity of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Mouse Intestine: Overlapping Distribution with Sulfotransferases

  2007cited by this paper
• Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients

  2007cited by this paper
• Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.

  2007cited by this paper
• Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats

  2007cited by this paper
• Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats

  2007cited by this paper
• Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides.

  2006cited by this paper
• Expression and function of efflux drug transporters in the intestine.

  2006cited by this paper
• MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.

  2006cited by this paper
• Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.

  2006cited by this paper
• Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6.

  2006cited by this paper
• Effects of renal failure on drug transport and metabolism.

  2006cited by this paper
• An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.

  2006cited by this paper
• Molecular interactions between dipeptides, drugs and the human intestinal H+–oligopeptide cotransporter hPEPT1

  2006cited by this paper
• Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

  2006cited by this paper
• Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells.

  2006cited by this paper
• Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants

  2006cited by this paper
• Function of multidrug resistance-associated protein 2 in acute hepatic failure rats.

  2006cited by this paper
• Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse

  2006cited by this paper
• The complexity of intestinal absorption and exsorption of digoxin in rats.

  2006cited by this paper
• Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.

  2006cited by this paper
• BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION

  2006cited by this paper
• Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)

  2006cited by this paper
• What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.

  2006cited by this paper
• Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.

  2006cited by this paper
• Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

  2006cited by this paper
• CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS

  2006cited by this paper
• Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells.

  2006cited by this paper
• Breast cancer resistance protein (BCRP/ABCG2).

  2005cited by this paper
• Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: Involvement of the suppression of intestinal cytochrome P450 3A and P‐glycoprotein

  2005cited by this paper
• Effect of ABCG2 genotype on the oral vioavailability of topotecan

  2005cited by this paper
• A Higher Dose Requirement of Tacrolimus in Active Crohn's Disease May Be Related to a High Intestinal P-Glycoprotein Content

  2005cited by this paper
• Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin

  2005cited by this paper
• Transporter‐mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG‐CoA reductase

  2005cited by this paper
• Role of the breast cancer resistance protein (ABCG2) in drug transport

  2005cited by this paper
• Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.

  2005cited by this paper
• Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.

  2005cited by this paper
• DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1

  2005cited by this paper
• Increased bioavailability of tacrolimus after rectal administration in rats.

  2004cited by this paper
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• Differential Multidrug Resistance-Associated Protein 1 through 6 Isoform Expression and Function in Human Intestinal Epithelial Caco-2 Cells

  2004cited by this paper
• Increased hepatic and renal expressions of multidrug resistance‐associated protein 3 in Eisai hyperbilirubinuria rats

  2004cited by this paper
• Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans

  2004cited by this paper
• Transport Activity of Human MRP3 Expressed in Sf9 Cells: Comparative Studies with Rat MRP3

  2004cited by this paper
• Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes.

  2004cited by this paper
• Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients.

  2004cited by this paper
• Tacrolimus Therapy According to Mucosal MDR1 Levels in Small‐bowel Transplant Recipients

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability.

  2004cited by this paper
• CYP3A4 and P‐Glycoprotein Activity in Healthy Controls and Transplant Patients on Cyclosporin vs. Tacrolimus vs. Sirolimus

  2004cited by this paper
• Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes.

  2004cited by this paper
• Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and beta-methyldigoxin in rats.

  2003cited by this paper
• Differential Effect of Acute Hepatic Failure on in Vivo and in Vitro P-Glycoprotein Functions in the Intestine

  2003cited by this paper
• Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

  2003cited by this paper
• Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3.

  2003cited by this paper
• Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development.

  2003cited by this paper
• Impact of Drug Transporter Studies on Drug Discovery and Development

  2003cited by this paper
• Enhanced expression of enterocyte P‐glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation

  2003cited by this paper
• Outcome from integrated pain management treatment for recovering substance abusers.

  2003cited by this paper
• P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine

  2003cited by this paper
• The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

  2003cited by this paper
• The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine

  2003cited by this paper
• Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.

  2003cited by this paper
• Quantitative Evaluation of the Function of Small Intestinal P-Glycoprotein: Comparative Studies Between in Situ and in Vitro

  2003cited by this paper
• P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans

  2003cited by this paper
• The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.

  2003cited by this paper
• Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

  2003cited by this paper
• Interaction of endogenous compounds in human and rat urine with P-glycoprotein.

  2002cited by this paper
• Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).

  2002cited by this paper
• Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition.

  2002cited by this paper
• Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states.

  2002cited by this paper
• Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine.

  2002cited by this paper
• Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

  2002cited by this paper
• Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.

  2001cited by this paper
• P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.

  2001cited by this paper
• Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

  2001cited by this paper
• Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12.

  2001cited by this paper
• Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily.

  2001cited by this paper
• Expression and function of P‐glycoprotein in rats with carbon tetrachloride‐induced acute hepatic failure

  2001cited by this paper
• Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.

  2001cited by this paper
• Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.

  2001cited by this paper
• ATP-dependent Transport of Bile Salts by Rat Multidrug Resistance-associated Protein 3 (Mrp3)*

  2000cited by this paper
• Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.

  2000cited by this paper
• Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

  2000cited by this paper
• Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

  2000cited by this paper
• Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure.

  2000cited by this paper
• Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.

  1999cited by this paper
• Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

  1999cited by this paper
• Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane

  1999cited by this paper
• Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.

  1999cited by this paper

• Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions

  2026cites this paper
• Inulin Reverses Intestinal Mrp2 Downregulation in a Diet-Induced Obesity Mouse Model: Role of Intestinal Microbiota as a Pivotal Modulator

  2025cites this paper
• Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications

  2025cites this paper
• Sensory signals for nausea

  2025cites this paper
• Herb-Drug Interaction Between Sailuotong and Pitavastatin: A Systematic Pharmacokinetic Investigation and Mechanism Analysis

  2025cites this paper
• Effect of luteolin on ceftiofur intestinal absorption: the rational use of Caco-2 monolayer cell model and everted gut sac model

  2025cites this paper
• Enhancement in the intestinal absorption of ginsenoside Re by ginseng polysaccharides and its mechanisms.

  2025cites this paper
• Comparative Analysis of Caco-2 Cells and Human Jejunal and Duodenal Enteroid-Derived Cells in Gel- and Membrane-Based Barrier Models of Intestinal Permeability.

  2025cites this paper
• Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies.

  2025cites this paper
• Herb‐drug interactions: A short review on central and peripheral nervous system drugs

  2024cites this paper
• Accessing anti-HIV activity through the attenuation of USP18 activity: novel insights from molecular dynamic simulations, free-energy profiling, and multi-cellular inhibition assays

  2024cites this paper
• Advances in Modeling Approaches for Oral Drug Delivery: Artificial Intelligence, Physiologically-Based Pharmacokinetics, and First-Principles Models

  2024cites this paper
• Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.

  2023cites this paper
• Lipid-Based Nanoparticles as Oral Drug Delivery Systems: Overcoming Poor Gastrointestinal Absorption and Enhancing Bioavailability of Peptide and Protein Therapeutics

  2023cites this paper
• Review Article Lipid-based nanoparticles as oral drug delivery systems: overcoming poor gastrointestinal absorption and enhancing bioavailability of peptide/protein-based drugs

  2023cites this paper
• Changes in Expression and Function of Placental and Intestinal P-gp and BCRP Transporters during Pregnancy

  2023cites this paper
• Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations

  2023cites this paper
• Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties

  2023cites this paper
• Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth

  2023cites this paper
• Oil-Based Delivery Control Release System Targeted to the Later Part of the Gastrointestinal Tract—A Mechanistic Study

  2022cites this paper
• A review: Pharmacokinetics and pharmacology of aminoalcohol-diterpenoid alkaloids from Aconitum species.

  2022cites this paper
• Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery

  2022cites this paper
• TNF-α and IL-1β Exposure Modulates the Expression and Functionality of P-Glycoprotein in Intestinal and Renal Barriers.

  2022cites this paper
• Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)–but how?

  2022cites this paper
• Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery

  2022cites this paper
• QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats

  2022cites this paper
• Advances in Oral Drug Delivery

  2021influential citation
• Inflammation Induces Changes in the Functional Expression of P-gp, BCRP, and MRP2: An Overview of Different Models and Consequences for Drug Disposition

  2021cites this paper
• Anticancer potential of Naringenin, Biosynthesis, Molecular target, and structural perspectives.

  2021cites this paper
• Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption

  2021cites this paper
• Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances.

  2021cites this paper
• Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs.

  2021cites this paper
• Bioaccessibility and Absorption of Flavonoid C-glycosides from Abrus mollis Using Simulated Digestion, Caco-2 Cell, and In Situ Single-pass Perfusion Models

  2021cites this paper
• Changes induced by chronic exposure to high arsenic concentrations in the intestine and its microenvironment.

  2021cites this paper
• Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs

  2021cites this paper
• Effect of GenX on P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance–Associated Protein 2 at the Blood–Brain Barrier

  2020cites this paper
• Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early—Stage Drug Development

  2020cites this paper
• Acyclovir-Loaded Solid Lipid Nanoparticles: Optimization, Characterization and Evaluation of Its Pharmacokinetic Profile

  2020cites this paper
• Inhibition of Breast Cancer Resistance Protein (BCRP) by Ko143 Can Affect Pharmacokinetics of Enrofloxacin in Exopalaemon carinicauda

  2020cites this paper
• Nutraceutical nanodelivery; an insight into the bioaccessibility/bioavailability of different bioactive compounds loaded within nanocarriers

  2020cites this paper
• Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies

  2020cites this paper
• Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades.

  2020cites this paper
• Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats

  2020cites this paper
• The grouping and assessment strategy for organic pigments (GRAPE): Scientific evidence to facilitate regulatory decision-making.

  2019cites this paper
• Development of a novel in vitro 3D intestinal model for permeability evaluations

  2019cites this paper
• Modulation of expression/function of intestinal P-glycoprotein under disease states

  2019cites this paper
• Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability

  2019cites this paper
• What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs

  2019cites this paper
• Different modulation of Panax notoginseng on the absorption profiling of triptolide and tripterine from Tripterygium wilfordii in rat intestine

  2018cites this paper
• Interactions of pesticides with membrane drug transporters: implications for toxicokinetics and toxicity

  2018cites this paper
• iPSC-Derived Enterocyte-like Cells for Drug Absorption and Metabolism Studies.

  2018cites this paper
• P‐glycoprotein expression in the gastrointestinal tract of male and female rats is influenced differently by food

  2018cites this paper
• Potential P‐glycoprotein‐mediated herb‐drug interaction of phyllanthin at the intestinal absorptive barrier

  2018cites this paper
• Exploring the Chemical Space of P-Glycoprotein Interacting Compounds.

  2017cites this paper
• Parameterization of In Silico Oral Disposition Models: Focus on Pediatrics

  2017cites this paper
• Cancer chemoprevention through dietary flavonoids: what’s limiting?

  2017cites this paper
• Pharmacokinetic interaction of green tea beverage containing cyclodextrins and high concentration catechins with P‐glycoprotein substrates in LLC‐GA5‐COL150 cells in vitro and in the small intestine of rats in vivo

  2017cites this paper
• Absorption sites of orally administered drugs in the small intestine

  2017cites this paper
• Intestinal absorption and metabolism of bush tea major phenolic compounds exhibiting anti-diabetic activity.

  2017cites this paper
• Modulation of P-glycoprotein Expression and Function under Disease States in Rats and Humans

  2017cites this paper
• Polyphenols Beyond Barriers: A Glimpse into the Brain

  2017cites this paper
• Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models

  2017cites this paper
• Modulation of multidrug resistance‐associated proteins function in erythrocytes in glycerol‐induced acute renal failure rats

  2017cites this paper
• Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers

  2017cites this paper
• The effects of dietary and herbal phytochemicals on drug transporters☆

  2017cites this paper
• Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP

  2017cites this paper
• Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery.

  2017cites this paper
• A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability.

  2016cites this paper
• Reduced Oral Bioavailability and Altered Pharmacokinetics of Saquinavir by Co-administration with Biochanin A in Rats

  2016cites this paper
• Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

  2016influential citation
• P-glycoprotein transporter in drug development

  2016cites this paper
• A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.

  2016cites this paper
• Guest editorial: P-GLYCOPROTEIN TRANSPORTER IN DRUG DEVELOPMENT

  2016cites this paper
• Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats

  2016cites this paper
• Food macromolecule based nanodelivery systems for enhancing the bioavailability of polyphenols

  2016cites this paper
• Effect of cigarette smoke extract on P-glycoprotein function in primary cultured and newly developed alveolar epithelial cells.

  2016cites this paper
• Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.

  2016cites this paper
• Topología molecular aplicada al reconocimiento de sustratos de la Proteína de Resistencia del Cáncer de Mama (BCRP)

  2016cites this paper
• Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in Mice

  2016cites this paper
• Resveratrol-mediated reversal of tumor multi-drug resistance.

  2015cites this paper
• Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells

  2015cites this paper
• Upregulation of P‐glycoprotein expression by ophthalmic drugs in different corneal in‐vitro models

  2015cites this paper
• Investigation of Low Bioavailability Using Physiologically Based Pharmacokinetic Modeling: A Case Example (Lassbio-596)

  2015influential citation
• Disposition of flavonoids impacts their efficacy and safety.

  2015cites this paper
• Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance

  2014cites this paper
• Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy.

  2014cites this paper
• Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.

  2014cites this paper
• An evaluation of the latest in vitro tools for drug metabolism studies

  2014cites this paper
• Applications of a 7-day Caco-2 cell model in drug discovery and development.

  2014cites this paper
• Interaction of hydrophobic components in female urine before and after childbirth with P-glycoprotein in vitro.

  2014cites this paper
• Dietary factors affecting polyphenol bioavailability.

  2014cites this paper
• Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.

  2014cites this paper
• Extrahepatic metabolism at the body's internal–external interfaces

  2014cites this paper
• Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions.

  2014cites this paper
• Expression of the ABC transport proteins MDR1 (ABCB1) and BCRP (ABCG2) in bovine rumen

  2014cites this paper
• Can ion pairing mediate drug uptake via active carriers ?

  2014cites this paper
• Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence

  2014cites this paper
• Development of an Improved Three-Dimensional In Vitro Intestinal Mucosa Model for Drug Absorption Evaluation

  2013cites this paper
• Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.

  2013cites this paper
• Bioavailability of hop-derived bitter acids : key factors for the health-beneficial properties of beer

  2013cites this paper